This trend was also suitable for the mutation frequencies of KRAS and APC. Collectively, the discovery of genomic profiling among NSCLC subtypes (LUAD, LUSC, and large-cell carcinoma) could also benefit a lot from ctDNA. The gene discussed is KRAS; the disease is large cell carcinoma.